CN1166402C - Composite Chinese medicine with health care function - Google Patents
Composite Chinese medicine with health care function Download PDFInfo
- Publication number
- CN1166402C CN1166402C CNB011186186A CN01118618A CN1166402C CN 1166402 C CN1166402 C CN 1166402C CN B011186186 A CNB011186186 A CN B011186186A CN 01118618 A CN01118618 A CN 01118618A CN 1166402 C CN1166402 C CN 1166402C
- Authority
- CN
- China
- Prior art keywords
- group
- tried
- influence
- mice
- thing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a health-care product with functions of regulating immunity, resisting senility, resisting fatigue, exerting a tonic effect on the heart, strengthening bone, etc. The health-care product is prepared by using American ginseng, propolis, ganoderma spore powder and pearl powder as raw materials.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of have nourishing the five internal organs, heart tonifying bone strengthening, the Halth-care composition of health-care effects such as strengthening the body resistance and adjusting immunity and resisting fatigue.
Background technology
21 century, people's life quality improves day by day, and human theory to health has been not only diseases prevention, has cured the disease, but health care.The health nutrient industry develop rapidly epoch, the health promoting product that emerges in an endless stream enriches market.Especially the health product based on Chinese herbal medicine demonstrate powerful commercial viability.
The pharmacologically active of Radix Panacis Quinquefolii is many-sided, is considered to the food medicine of YIN nourishing, pathogenic fire purging, tonification from ancient times; Contain abundant mineral in the propolis, trace element such as elements such as calcium, magnesium, potassium, sodium, phosphorus and ferrum, zinc, copper, manganese are arranged according to surveying and determination.Mineral is the composition of human body cell and organ-tissue, be the important component part and the activator of enzyme system, the effect of regulating and keeping body physiological function is arranged: Ganoderma is described as " Ganoderma " of strengthening the body resistance by China's successive dynasties medicine scholar, be called top grade by " herbal classic ", in recent years, the health-care effect of Ganoderma spore powder is also generally acknowledged by the scholar: the arresting convulsion of calming the nerves of the Chinese medicine that Margarita is known by many crowds, function, the removing nebula that makes eye bright, removing toxic substances and promoting granulation: be used for clinically arresting convulsion, insomnia; Cool breeze epilepsy, order are given birth to cataracta, and the infections skin ulcer is not held back etc., and Margarita is again the beauty treatment treasure of generally acknowledging, has the ability of removing human body ultra-oxygen anion free radical and hydroxyl radical free radical.
Summary of the invention
The object of the invention is to provide a kind of have heart tonifying bone strengthening, strengthening the body resistance, regulates the Chinese medicine composition of health-care effects such as immunity and resisting fatigue.
Technical solution of the present invention is achieved in that chooses following bulk drugs:
Radix Panacis Quinquefolii 500～1000 weight portion propolis 500～1000 weight portions
Ganoderma spore powder 1000-2000 weight portion Margarita powder 500～1500 weight portions
Above-mentioned raw materials according to common process, is made any health product acceptable forms.As capsule, oral liquid, chewable tablet etc.
Product of the present invention (board four precious vigor capsules are opened in the west) confirms to have immunoregulation effect and antifatigue effect through scientific experiments.
2. result
2.1 influence to normal mouse thymus/body weight, spleen/body weight and body weight
Board four precious vivocon capsules are opened to the influence＜X of normal mouse thymus/body weight ratio ± SD) in table 1 west
Group dosage (g/kg.Bw) number of animals (only) thymus/body weight ratio (mg/g) P value
Blank group 0 12 2.37 ± 0.29-
Low dose group 0.2 12 2.47 ± 0.62 0.6245
Middle dosage group 0.4 12 2.27 ± 0.58 0.6026
High dose group 1.2 12 2.26 ± 0.60 0.7130
By table 1 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, each dosage group thymus/body weight ratio does not all have significant difference (p＞0.05).
Board four precious vivocon capsules are opened to the influence of normal mouse spleen/body weight ratio (X ± SD) in table 2 west
| Group | Dosage (g/kg.bw) | Number of animals (only) | Spleen/body weight ratio (mg/g) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.2 0.4 1.2 | 12 12 12 12 | 5.05±1.26 5.73±0.88 5.24±0.82 5.56±1.03 | - 0.1434 0.6657 0.4095 |
By table 2 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, each dosage group spleen/body weight ratio does not all have significant difference (p＞0.05).
Board four precious vivocon capsules are opened to the influence of normal mouse body weight (X ± SD) in table 3 west
Dosage number of animals experiment precursor intense excess syndrome is tested the back body weight
Group P value P value
(g/kg.bw) (only) (g) (g)
Blank group 0 12 19.3 ± 1.1-32.9 ± 2.5-
Low dose group 0.2 12 19.5 ± 1.5 0.7571 32.0 ± 2.4 0.3740
Middle dosage group 0.4 12 19.1 ± 0.8 0.4793 32.8 ± 2.3 0.9466
High dose group 1.2 12 19.2 ± 0.8 0.6708 31.4 ± 2.7 0.1677
By table 3 as seen, per os give the mice various dose tried before the thing and after 4 weeks, with matched group relatively, each dosage group body weight does not all have outstanding difference (p＞0.05).
2.2 influence to the inductive mouse lymphocyte conversion of ConA
The influence that board four precious vivocon capsules transform the inductive mouse lymphocyte of ConA (X ± SD) is opened in table 4 west
Unit: optical density value
Group dosage (g/kg.bw) number of animals (only) lymphopoiesis ability P value
Blank group 0 12 0.032 ± 0.027-
Low dose group 0.2 12 0.031 ± 0.025 0.8832
Middle dosage group 0.4 12 0.047 ± 0.028 0.2413
High dose group 1.2 12 0.036 ± 0.027 0.7352
By table 4 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, each dosage group lymphopoiesis ability does not have significant difference (p＞0.05).
2.3 influence to normal mouse delayed allergy (DTH)
Board four precious vivocon capsules are opened to the influence of normal mouse delayed allergy (X ± SD) in table 5 west
Group dosage (g/kg.bw) number of animals (only) swelling degree of the paw difference (mm) P value
Blank group 0 12 0.57 ± 0.28-
Low dose group 0.2 12 0.46 ± 0.24 0.5377
Middle dosage group 0.4 12 0.54 ± 0.20 0.7531
High dose group 1.2 12 0.52 ± 0.19 0.8831
By table 5 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the swelling degree of the paw of each dosage group does not all have significant difference (p＞0.05).
2.4 influence to normal mouse antibodies cellulation
Board four precious vivocon capsules are opened to the influence of normal mouse PFC (X ± SD) in table 6 west
Group dosage (g/kg, bw) number of animals (only) PFC P value
Blank group 0 12 4.91 ± 0.23-
Low dose group 0.2 12 5.17 ± 0.19
*0.0071
Middle dosage group 0.4 12 5.13 ± 0.21
*0.0269
High dose group 1.2 12 5.10 ± 0.10
*0.0171
*: with matched group significant difference (p＜0.05) is arranged relatively
*: with matched group significant differences (p＜0.01) is arranged relatively
By table 6 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the PFC quantity of basic, normal, high dosage group improves 5% (p＜0.01), 4% (p＜0.05), 4% (p＜0.05) respectively.
2.5 influence to normal mice serum hemolysin
Board four precious vivocon capsules are opened to the influence of normal mice serum hemolysin (X ± SD) in table 7 west
Group dosage (g/kg.bw) number of animals (only) HC50 P value
Blank group 0 12 189.7 ± 75.4-
Low dose group 0.2 12 255.6 ± 23.2
*0.0084
Middle dosage group 0.4 12 229.1 ± 51.1 0.1477
High dose group 1.2 12 210.8 ± 65.1 0.4707
*: with matched group significant differences (p＜0.01) is arranged relatively
By table 7 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the HC50 of low dose group improves 35% (p＜0.01).
2.6 influence to normal macrophage phagocytosis of mice
The influence that board four precious vivocon capsules clean up the carbon of normal mouse (X ± SD) is opened in table 8 west
Group dosage (g/kg.bw) number of animals (only) α P value
Blank group 0 12 6.06 ± 0.81-
Low dose group 0.2 12 6.17 ± 0.91 0.7708
Middle dosage group 0.4 12 6.39 ± 0.67 0.2958
High dose group 1.2 12 6.24 ± 0.61 0.2385
By table 8 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the carbon of each dosage group is cleaned up index does not all have significant difference (p＞0.05).
The influence of board four precious vivocon capsules to the macrophage phagocytic rate of normal mouse opened in table 9 west
Group dosage (g/kg.bw) number of animals (only) phagocytic rate (%) P value
Blank group 0 12 23 ± 10-
Low dose group 0.2 12 36 ± 9
*0.0031
Middle dosage group 0.4 12 43 ± 14
* *0.0004
High dose group 1.2 12 35 ± 8
*0.0042
*: with matched group significant differences (p＜0.01) is arranged relatively
* *: with matched group utmost point significant difference (p＜0.01) is arranged relatively
By table 9 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the macrophage phagocytic rate of basic, normal, high dosage group improves 54% (p＜0.01), 85% (p＜0.001) and 49% (p＜0.01) respectively.
Board four precious vivocon capsules are opened to the exponential influence of the macrophage phagocytic of normal mouse in table 10 west
Group dosage (g/kg.bw) number of animals (only) phagocytic index P value
Blank group 0 12 0.44 ± 0.23-
Low dose group 0.2 12 0.70 ± 0.22
*0.0085
Middle dosage group 0.4 12 0.85 ± 0.33
*0.0016
High dose group 1.2 12 0.63 ± 0.14
*0.0205
*: with matched group significant difference (p＜0.05) is arranged relatively
*: with matched group significant differences (p＜0.01) is arranged relatively
By table 10 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with matched group relatively, the macrophage phagocytic index of basic, normal, high dosage group improves 59% (p＜0.01), 93% (p＜0.01) respectively.With 43% (p＜0.05).
3 brief summaries
Per os gives the west of mice various dose and opens board four precious vivocon capsules after 4 weeks, compare with matched group, the antibody-producting cell quantity of low dose group (0.2g/kg.bw) improves 5% (p＜0.01), serum hemolysin HC50 improves 35% (p＜0.01), and the macrophage phagocytic rate improves 54% (p＜0.01).The macrophage phagocytic index improves 59% (p＜0.01).All other indexs all do not have significant difference (p＜0.05).The antibody-producting cell quantity of middle dosage group (0.4g/kg.bw) improves 4% (p＜0.05), and the macrophage phagocytic rate improves 85% (p＜0.001), and the macrophage phagocytic index improves 93% (p＜0.01).All other indexs all do not have significant difference (p＞0.05).The antibody-producting cell quantity of high dose group (1.2g/kg.bw) improves 4% (p＜0.05), and the macrophage phagocytic rate improves 49% (p＜0.01), and the macrophage phagocytic index improves 43% (p＞0.05).All other indexs all do not have significant difference (p＞0.05).Body weight, thymus/body weight ratio, spleen/body weight ratio all do not have significant difference (p＞0.05) before and after the experiment.
The present invention also proves its antifatigue effect through zoopery.Result as shown in the table 2.1 is tried the influence of thing to the mice body weight
Table 1 is tried thing to the influence of mice body weight test (X ± SD)
Tried agent amount number of animals and tried thing 39 to trying preceding the giving of thing
Animal grouping P value P value
(g/kgbw) (only) body weight (g) day back body weight (g)
Blank group 0 12 20.9 ± 1.7-38.3 ± 5.2-
Low dose group 0.2 12 20.6 ± 1.3 0.6229 36.2 ± 2.3 0.2129
Middle dosage group 0.4 12 20.5 ± 1.6 0.5975 38.1 ± 5.0 0.9309
High dose group 1.2 12 21.2 ± 2.0 0.6573 37.9 ± 4.9 0.8385
By table 1 as seen, per os gives different being tried of mice and compares with the blank group 4 week of thing front and back, and each dosage group body weight does not all have significant difference (p＞0.05).
2.2 tried the influence of thing to the mice swimming test
Table 2 is tried thing to the influence of mice swimming test (X ± SD)
Tried agent amount number of animals swimming time
Animal grouping P value
(g/kg.bw) (only) (min)
Blank group 0 12 11.1 ± 7.0-
Low dose group 0.2 12 26.9 ± 14.7
*0.0027
Middle dosage group 0.4 12 23.3 ± 18.9
*0.0469
High dose group 1.2 12 25.0 ± 18.9
*0.0255
*: relatively there were significant differences (p＜0.05) with the blank group
*: with the blank group highly significant difference (p＜0.01) is arranged relatively
By table 2 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, basic, normal, high dosage group swimming time prolongs 142% (p＜0.01), 110% (p＜0.05), 125% (p＜0.05) respectively.
2.3 tried the influence of thing to the mice pole-jump test
Table 3 is tried thing to the influence of mice pole-jump test (X ± SD)
Tried the agent amount number of animals pole-climbing time
Animal grouping P value
(g/kg.bw) (only) (min)
Blank group 0 12 5.5 ± 1.9-
Low dose group 0.2 12 11.6 ± 5.9
*0.0025
Middle dosage group 0.4 12 14.7 ± 11.8
*0.0135
High dose group 1.2 12 13.0 ± 10.7
*0.0263
*: relatively there were significant differences (p＜0.05) with the blank group.
*: with blank highly significant difference (p＜0.01) is arranged relatively
By table 3 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, the basic, normal, high dosage group pole-climbing time prolongs 111% (p＜0.01), 167% (p＜0.05) and 136% (p＜0.05) respectively.
2.4 tried the influence of thing to the mice serum blood urea nitrogen
Table 4 is tried thing to the influence of mice serum blood urea nitrogen (X ± SD)
Tried agent amount number of animals serum urea nitrogen
Animal grouping P value
(g/kg.bw) (only) (mg/dL)
Blank group 0 12 25.6 ± 3.5-
Low dose group 0.2 12 23.1 ± 4.0 0.1051
Middle dosage group 0.4 12 25.4 ± 2.3 0.8697
High dose group 1.2 12 22.2 ± 3.7
*0.0289
*: relatively there were significant differences (p＜0.05) with the blank group.
By table 4 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, the high dose group urea nitrogen content reduces by 13% (p＜0.05).
2.5 tried the influence of thing to mice blood lactic acid
Table 5 is tried thing to the influence of mice blood lactic acid (swimming before) (X ± SD)
Being tried agent amount number of animals blood lactic acid concn swims
Animal grouping P value
(g/kg.bw) before (only) swimming (mg/dL)
Blank group 0 12 15.7 ± 4.8-
Low dose group 0.2 12 12.9 ± 4.8 0.1668
Middle dosage group 0.4 12 15.2 ± 4.1 0.7715
High dose group 1.2 12 15.1 ± 5.2 0.7580
By table 5 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, the blood lactic acid concn does not all have significant difference (p＞0.05) before each dosage group swimming.
Table 6 is tried the influence (X ± SD) of thing mice blood lactic acid (swimming back 0min)
Being tried agent amount number of animals blood lactic acid concn swims
Animal grouping P value
(g/kg.bw) (only) back 0min (mg/dL)
Blank group 0 12 41.7 ± 12.7-
Low dose group 0.2 12 43.9 ± 10.1 0.6531
Middle dosage group 0.4 12 52.9 ± 26.7 0.2040
High dose group 1.2 12 44.9 ± 8.6 0.4849
By table 6 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, each dosage group swimming back 0min blood lactic acid concn does not all have significant difference (p＞0.05).
Table 7 is tried thing to the influence of mice blood lactic acid (swimming back 20min) (X ± SD)
Being tried agent amount number of animals blood lactic acid concn swims
Animal grouping P value
(g/kg.bw) (only) back 0min (mg/dL)
Blank group 0 12 16.1 ± 4.4-
Low dose group 0.2 12 16.5 ± 5.9 0.8372
Middle dosage group 0.4 12 15.5 ± 5.5 0.7833
High dose group 1.2 12 13.4 ± 4.7 0.1712
By table 7 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, each dosage group swimming back 20min blood lactic acid concn does not all have significant difference (p＞0.05).
Table 8 is tried thing to the influence of mice blood lactic acid rising ratio (X ± SD)
Tried agent amount number of animals
Animal grouping blood lactic acid rising ratio P value
(g/kg.bw) (only)
Blank group 0 12 1.84 ± 1.15-
Low dose group 0.2 12 2.79 ± 1.46 0.0902
Middle dosage group 0.4 12 2.76 ± 2.13 0.2010
High dose group 1.2 12 2.32 ± 1.32 0.3507
By table 8 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, each dosage group swimming back 0min blood lactic acid rising ratio does not all have significant difference (p＞0.05).
Table 9 is tried thing is eliminated ratio to mice blood lactic acid influence (X ± SD)
Tried agent amount number of animals
Animal grouping blood lactic acid is eliminated ratio P value
(g/kg.bw) (only)
Blank group 0 12 0.58 ± 0.18-
Low dose group 0.2 12 0.61 ± 0.12 0.5571
Middle dosage group 0.4 12 0.66 ± 0.17 0.2412
High dose group 1.2 12 0.70 ± 0.10
*0.0480
*: relatively there were significant differences (p＞0.05) with the blank group
By table 9 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, high dose group swimming back 20min blood lactic acid is eliminated ratio and is improved 21% (p＜0.05).
2.6 tried the influence of thing to the Mouse Liver glycogen
Table 10 is tried the influence (X ± SD) of thing Mouse Liver glycogen
Tried agent amount number of animals hepatic glycogen
Animal grouping P value
(g/kg.bw) (only) (g/100g liver)
Blank group 0 12 4.19 ± 1.33-
Low dose group 0.2 12 3.70 ± 1.08 0.3369
Middle dosage group 0.4 12 4.30 ± 0.95 0.8245
High dose group 1.2 12 3.69 ± 0.48 0.2289
By table 10 as seen, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, each dosage group hepatic glycogen content does not all have significant difference (p＞0.05).
3. brief summary
Per os gives the various dose west and opens board four precious vivocon capsules after 4 weeks, compare with the blank group, low dose group (0.2g/kg.bw) swimming time prolongs 142% (p＜0.01), pole-climbing time lengthening 111% (p＜0.01), other each index there are no significant difference (p＞0.05); In dosage group (0.4g/kg.bw) swimming time prolong 110% (p＜0.05), pole-climbing time lengthening 167% (p＜0.05), blood lactic acid, serum urea nitrogen content, hepatic glycogen content there are no significant difference (p＞0.05); High dose group (1.2g/kg.bw) swimming time prolongs 125% (p＜0.05), pole-climbing time lengthening 136% (p＜0.05) serum urea nitrogen content reduces by 13% (p＜0.05), blood lactic acid is eliminated ratio and is improved 21% (p＜0.05), hepatic glycogen content there was no significant difference (p＞0.05).Each dosage group body weight does not all have significant difference (p＞0.05).
Embodiment: it is as follows to get raw material:
Radix Panacis Quinquefolii 750kg propolis 750kg
Ganoderma spore powder 150kg Margarita powder 1000kg
Preparation technology:
1. 100 orders are crossed in the selected pulverizing of Radix Panacis Quinquefolii, get fine powder A.
2. the preparation of propolis powder:
Take by weighing a mao glue (gel content is greater than 45%), with 95%, 85%, 75% edible ethanol dipping, dissolving, 24 hours after-filtration merge three times filtrate, through recovered alcohol, place under-4 ℃ of conditions with the propolis concentrated solution, are dried to powder, get fine powder B successively.
3. Ganoderma spore powder, Margarita powder are all crossed 100 mesh sieves and are got fine powder and A, B powder mixing, make 1000, the fill capsule, finished product, Co is packed in check
60The 8KGY irradiation sterilization, warehouse-in.
Claims (2)
1, a kind of compositions with health role is characterized in that the raw material of said composition is:
Radix Panacis Quinquefolii 500～1000 weight portion propolis 500～1000 weight portions
Ganoderma spore powder 1000～2000 weight portion Margarita powder 500～1500 weight portions.
2, compositions as claimed in claim 1 is characterized in that the raw material of said composition is;
Radix Panacis Quinquefolii 750 weight portion propolis 750 weight portions
Ganoderma spore powder 1500 weight portion Margarita powder 1000 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011186186A CN1166402C (en) | 2001-06-05 | 2001-06-05 | Composite Chinese medicine with health care function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011186186A CN1166402C (en) | 2001-06-05 | 2001-06-05 | Composite Chinese medicine with health care function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1389265A CN1389265A (en) | 2003-01-08 |
| CN1166402C true CN1166402C (en) | 2004-09-15 |
Family
ID=4663316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011186186A Expired - Fee Related CN1166402C (en) | 2001-06-05 | 2001-06-05 | Composite Chinese medicine with health care function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1166402C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141836A (en) * | 2013-02-21 | 2013-06-12 | 汤臣倍健股份有限公司 | Weight reducing capsule capable of enhancing immunity functions |
| CN104585732B (en) * | 2014-12-30 | 2016-05-18 | 广州白云山汉方现代药业有限公司 | A kind of Reishi sporule health food and preparation method thereof is applied with alleviating physical fatigue |
| CN107372954A (en) * | 2017-07-28 | 2017-11-24 | 明光市昊昊蜂业有限公司 | A kind of propolis beautifying tea |
| CN108991453A (en) * | 2018-08-06 | 2018-12-14 | 重庆市畜牧科学院 | A kind of preparation method and products thereof of compound nano-propolis |
| CN112618589A (en) * | 2021-01-04 | 2021-04-09 | 王喆鑫 | Traditional Chinese medicine health-care medicine formula and preparation method thereof |
-
2001
- 2001-06-05 CN CNB011186186A patent/CN1166402C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1389265A (en) | 2003-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1211107C (en) | Mixture for improving blood circulation | |
| CN1631247A (en) | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof | |
| CN1840171A (en) | Nutrition liquid for chronic nephropathy and preparation method thereof | |
| CN1166402C (en) | Composite Chinese medicine with health care function | |
| CN1033000A (en) | The magnesium additive of nutrients, feed and medicine | |
| CN1883527A (en) | A health product of lucid ganoderma and preparation method thereof | |
| CN1868463A (en) | Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN101041024A (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| CN1768744A (en) | Method for preparing compound famotidine chewing tablet | |
| CN1562337A (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1212141C (en) | Application of atractylodes rhizome oil in preparing medicine for osteoporosis | |
| CN1869208A (en) | Preparation of caterpillar fungus SOD and health-care product containing caterpillar fungus SOD | |
| CN1651036A (en) | Angelica root mistletoe granules and its preparation method | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1686405A (en) | Child intestine and stomach health effervescence tablet and its preparation method | |
| CN1293983A (en) | Hypolipemic medicine and its preparing process and application | |
| CN1500487A (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1228079C (en) | Oral medicine for treating child restless syndrome | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1304021C (en) | Medicinal composition and its preparing method | |
| CN1247211C (en) | Health-care or medicinal tablet containing active ganoderma extract | |
| CN1533805A (en) | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method | |
| CN1546087A (en) | Heart and brain nourishing products consisted of gadol mainly and its preparation | |
| CN100340239C (en) | Andrographolide dispersing tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: BEIJING SHENGGUOTAI TECHNOLOGY CO., LTD. Free format text: FORMER NAME OR ADDRESS: BEIJING XIKAIGUOTAI MEDICINE SCI-TECH CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 100013, 28 North Third Ring Road, Beijing Yi Building, room 1608 Patentee after: Beijing Saint Pacific Science and Technology Co., Ltd. Address before: 100027 No. 7, Dongxing Road, Beijing, Chaoyang District Patentee before: Beijing Xikaiguotai Medicine Sci-Tech Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHANG MINGLI Free format text: FORMER OWNER: BEIJING SHENGGUOTAI TECHNOLOGY CO., LTD. Effective date: 20070105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: 100102, room 1, unit 10, 601 south, Hua Fang, Chaoyang District, Beijing Patentee after: Zhang Mingli Address before: 100013, 28 North Third Ring Road, Beijing Yi Building, room 1608 Patentee before: Beijing Saint Pacific Science and Technology Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040915 Termination date: 20140605 |